Literature DB >> 29073552

Chemotherapy-induced cognitive impairments: White matter pathologies.

A Matsos1, M Loomes2, I Zhou2, E Macmillan2, I Sabel2, E Rotziokos2, W Beckwith2, I N Johnston2.   

Abstract

Whilst chemotherapeutic agents show promising results in the amelioration of cancerous tumors, patients often experience cognitive disturbances associated with chemotherapy long after treatment has ceased. Research has suggested that the structural integrity of white matter fibres in the brain are susceptible to the harmful effects of chemotherapy. Post-chemotherapy, white matter tracts often display altered morphology with a reduction in glial cells such as oligodendrocytes. Demyelination, gliosis and leukoencephalopathy during or post chemotherapy is associated with changes in processing speed and IQ. Thus, understanding the relationship between chemotherapy, white matter damage and cognition is warranted. This review presents evidence for chemotherapy induced white matter damage highlighting the importance of implementing behavioral and pharmological strategies to prevent or reverse such acute toxicity in the brain.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Chemotherapy; Corpus callosum and processing speed; Myelin; White matter

Mesh:

Substances:

Year:  2017        PMID: 29073552     DOI: 10.1016/j.ctrv.2017.09.010

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  12 in total

1.  The effect of doxorubicin or cyclophosphamide treatment on auditory brainstem response in mice.

Authors:  Maxwell Hennings; Thane Fremouw
Journal:  Exp Brain Res       Date:  2022-09-19       Impact factor: 2.064

Review 2.  Cognitive complications of cancer and cancer-related treatments - Novel paradigms.

Authors:  Naomi Lomeli; Javier Lepe; Kalpna Gupta; Daniela A Bota
Journal:  Neurosci Lett       Date:  2021-02-11       Impact factor: 3.046

3.  Measuring decline in white matter integrity after systemic treatment for breast cancer: omitting skeletonization enhances sensitivity.

Authors:  Yasmin Mzayek; Michiel B de Ruiter; Hester S A Oldenburg; Liesbeth Reneman; Sanne B Schagen
Journal:  Brain Imaging Behav       Date:  2021-06       Impact factor: 3.978

Review 4.  Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases.

Authors:  Lien D Nguyen; Barbara E Ehrlich
Journal:  EMBO Mol Med       Date:  2020-04-29       Impact factor: 12.137

Review 5.  Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia.

Authors:  Candice E Crocker; Philip G Tibbo
Journal:  Front Pharmacol       Date:  2018-10-18       Impact factor: 5.810

6.  Monitoring neurocognitive functioning in childhood cancer survivors: evaluation of CogState computerized assessment and the Behavior Rating Inventory of Executive Function (BRIEF).

Authors:  Lyn M Balsamo; Hannah-Rose Mitchell; Wilhelmenia Ross; Catherine Metayer; Kristina K Hardy; Nina S Kadan-Lottick
Journal:  BMC Psychol       Date:  2019-05-02

Review 7.  REVIEW: MR elastography of brain tumors.

Authors:  Adomas Bunevicius; Katharina Schregel; Ralph Sinkus; Alexandra Golby; Samuel Patz
Journal:  Neuroimage Clin       Date:  2019-11-23       Impact factor: 4.881

8.  A Role of Microtubules in Oligodendrocyte Differentiation.

Authors:  Bo Yoon Lee; Eun-Mi Hur
Journal:  Int J Mol Sci       Date:  2020-02-05       Impact factor: 5.923

9.  Cyclophosphamide and epirubicin induce high apoptosis in microglia cells while epirubicin provokes DNA damage and microglial activation at sub-lethal concentrations.

Authors:  Rafael de la Hoz-Camacho; Ana Luisa Rivera-Lazarín; Jose Manuel Vázquez-Guillen; Diana Caballero-Hernández; Edgar Mendoza-Gamboa; Ana Carolina Martínez-Torres; Cristina Rodríguez-Padilla
Journal:  EXCLI J       Date:  2022-01-10       Impact factor: 4.068

Review 10.  The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors.

Authors:  Elizabeth Cooper; Peter J Choi; William A Denny; Jiney Jose; Mike Dragunow; Thomas I-H Park
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.